Insider Selling: Zynex, Inc. (NASDAQ:ZYXI) CEO Sells 2,000 Shares of Stock

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of the business’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $8.67, for a total transaction of $17,340.00. Following the transaction, the chief executive officer now owns 14,619,350 shares in the company, valued at $126,749,764.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Thomas Sandgaard also recently made the following trade(s):

• On Wednesday, November 6th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.82, for a total transaction of $17,640.00.
• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.63, for a total transaction of $17,260.00.
• On Wednesday, October 30th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.92, for a total transaction of $17,840.00.

Zynex Stock Performance

Shares of NASDAQ:ZYXI opened at $8.83 on Friday. The company’s 50 day moving average price is $8.15 and its two-hundred day moving average price is $9.00. Zynex, Inc. has a 12-month low of $7.15 and a 12-month high of $13.77. The firm has a market cap of $281.24 million, a PE ratio of 58.87 and a beta of 0.53. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66.

Zynex (NASDAQ:ZYXI) last announced its earnings results on Thursday, October 24th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The firm had revenue of $49.97 million for the quarter, compared to analyst estimates of $50.83 million. During the same quarter in the prior year, the business posted $0.10 EPS. The business’s revenue was up .1% compared to the same quarter last year. Equities research analysts predict that Zynex, Inc. will post 0.2 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Gladius Capital Management LP grew its position in shares of Zynex by 53.4% during the 3rd quarter. Gladius Capital Management LP now owns 5,002 shares of the company’s stock worth $41,000 after purchasing an additional 1,742 shares in the last quarter. Investment Partners Asset Management Inc. bought a new stake in shares of Zynex during the 3rd quarter worth approximately $96,000. Hsbc Holdings PLC bought a new stake in shares of Zynex during the 2nd quarter worth approximately $113,000. Quest Partners LLC lifted its holdings in shares of Zynex by 646.7% during the 2nd quarter. Quest Partners LLC now owns 12,926 shares of the company’s stock worth $120,000 after acquiring an additional 11,195 shares during the period. Finally, State Board of Administration of Florida Retirement System bought a new stake in shares of Zynex during the 1st quarter worth approximately $137,000. Institutional investors and hedge funds own 29.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on ZYXI shares. Royal Bank of Canada decreased their price target on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. HC Wainwright upped their price target on shares of Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, October 25th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.